Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progression.